Multiple Sclerosis Clinical Trial
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
Summary
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.
Full Description
The AC-058B303 study (extension study) is the long-term extension for the AC-058B301 study (core study). The core study has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with RMS. The subjects are treated with either ponesimod or the active comparator, teriflunomide in the core study. The purpose of this long term extension of the core study is to characterize the long-term safety and control of disease of ponesimod in subjects with RMS. In particular, the study will allow to observe potential adverse events which may only occur after long term treatment with ponesimod. The study will also investigate the effect of re-initiation of ponesimod after a brief interruption in a relatively large population (all subjects treated with ponesimod in the core study and eligible for the extension study) on disease activity in terms of relapses and MS-related MRI lesions. There is currently limited guidance on when a new MS treatment should be started after discontinuation of teriflunomide and the study will contribute with data on safety and efficacy of switching from teriflunomide to ponesimod after an interruption as mandated by the protocol. The study will also allow confirmation of sustained efficacy of ponesimod in terms of relapses, MRI lesions and reduction of disability accumulation during long-term treatment. In addition, combined data from the core study together with the results of the current extension study will allow comparison of MS activity in subjects who were switched from teriflunomide to ponesimod versus those who were treated with ponesimod in both studies. A vaccination sub-study will be conducted in a sub-set of up to 50 eligible study participants from selected countries who consent to be vaccinated with the Janssen coronavirus disease-2019 (COVID-19) vaccine (Ad26.COV2.S) to investigate the immune response induced by the Janssen COVID-19 vaccine.
Eligibility Criteria
Inclusion Criteria:
Signed informed consent
Subjects with MS having completed the double-blind treatment in the core study as scheduled
Compliance with teriflunomide elimination procedure
Women of childbearing potential (WOCBP) must have a negative pre-treatment urine pregnancy test, must agree to undertake 4-weekly urine pregnancy tests, and must have been using reliable methods of contraception. Fertile male subjects participating in the study must agree to use a condom.
Exclusion Criteria:
Any of the following cardiovascular conditions on Day 1 pre-dose:
Resting heart rate (HR) < 50 bpm;
Presence of second degree atrioventricular (AV) block or third degree AV block or a QTcF interval > 470 ms (females), > 450 ms (males);
Any of the following alerts from central laboratory at Visit 14 of the core study (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1 of the core study:
Lymphocyte count: < 0.2 x 109/L;
Neutrophil count <1.0 × 109/L;
Platelet count < 50 × 109/L;
Creatinine clearance < 30 mL/min
At Visit 14 of the core study (EOT) >30% decrease from core study baseline FEV1 and/or FVC;
Clinically significant, persistent respiratory AEs (e.g., dyspnea) not resolved prior to first dosing in the extension study.
Macular edema at any time between Visit 1 (Screening) in the core study and Day 1 of the extension study.
Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated visit FU2, or on Day 1 of the extension study pre-dose:
Suspected opportunistic infection of the CNS or any other infection which, in the opinion of the investigator, contraindicates re-start of the study drug;
Stevens-Johnson syndrome or toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms.
Need for and intention to administer forbidden study treatment-concomitant therapy
Women who are pregnant or lactating.
Male subjects wishing to parent a child;
Treatment with any MS Disease Modifying Therapies;
Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study;
Subjects unlikely to comply with the extension study protocol based on investigator best judgment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 145 Locations for this study
Carlsbad California, 92011, United States
Pomona California, 91767, United States
Denver Colorado, 80209, United States
Ormond Beach Florida, 32174, United States
Tampa Florida, 33612, United States
Indianapolis Indiana, 46256, United States
Raleigh North Carolina, 27607, United States
Columbus Ohio, 43214, United States
Franklin Tennessee, 37064, United States
Grodno , 23001, Belarus
Minsk , 22002, Belarus
Minsk , 22011, Belarus
Vitebsk , 21002, Belarus
Vitebsk , 21003, Belarus
Sarajevo , 71000, Bosnia and Herzegovina
Plovdiv , 4002, Bulgaria
Sofia , 1113, Bulgaria
Sofia , 1309, Bulgaria
Sofia , 1407, Bulgaria
Sofia , 1431, Bulgaria
Sofia , 1431, Bulgaria
Sofia , 1606, Bulgaria
Edmonton Alberta, T6G 1, Canada
Victoria British Columbia, V8R 1, Canada
Ottawa Ontario, K1H 8, Canada
Greenfield Park Quebec, J4V 2, Canada
Osijek , 31000, Croatia
Zagreb , 10000, Croatia
Brno , 65691, Czechia
Hradec Králové , 500 0, Czechia
Jihlava , 586 3, Czechia
Ostrava-Poruba , 708 5, Czechia
Pardubice , 532 0, Czechia
Praha 2 , 128 0, Czechia
Praha 5 , 150 0, Czechia
Teplice , 415 2, Czechia
Tampere , 33100, Finland
Turku , 20520, Finland
Bordeaux cedex , 33076, France
Clermont Ferrand Cedex 1 , 63003, France
Nantes Cedex 1 , 44093, France
Nice , 6000, France
Strasbourg CEDEX , 67091, France
T'bilisi , 0160, Georgia
Tbilisi , 112, Georgia
Tbilisi , 114, Georgia
Tbilisi , 179, Georgia
Tbilisi , 186, Georgia
Dresden , 1307, Germany
Erfurt , 99089, Germany
Leipzig , 04275, Germany
Mainz , 55131, Germany
Athens , 115 2, Greece
Athens , 11521, Greece
Marousi , 15125, Greece
Budapest , 1145, Hungary
Budapest , 1204, Hungary
Esztergom , 2500, Hungary
Győr , 9023, Hungary
Kistarcsa , 2143, Hungary
Ashkelon , 78306, Israel
Haifa , 31096, Israel
Jerusalem , 91120, Israel
Safed , 13043, Israel
L' Aquila , 67100, Italy
Roma , 189, Italy
Riga , 1002, Latvia
Riga , 1015, Latvia
Riga , LV-10, Latvia
Kaunas , LT501, Lithuania
Šiauliai , 76231, Lithuania
Chihuahua , 31203, Mexico
Nuevo Leon , 64060, Mexico
Bydgoszcz , 85-79, Poland
Gdansk , 80-80, Poland
Katowice , 40-57, Poland
Katowice , 40-68, Poland
Konstancin-Jeziorna , 05-51, Poland
Ksawerow , 95-05, Poland
Lublin , 20-41, Poland
Poznan , 60-35, Poland
Poznan , 61-73, Poland
Poznan , 61-85, Poland
Wrocław , 51-68, Poland
Braga , 4710-, Portugal
Coimbra , 3000-, Portugal
Lisboa , 1998-, Portugal
Porto , 4099-, Portugal
Bucuresti , 10825, Romania
Bucuresti , 22328, Romania
Bucuresti , 50098, Romania
Timisoara , 30072, Romania
Barnaul, Altai Krai , 65602, Russian Federation
Belgorod , 30800, Russian Federation
Bryansk , 24103, Russian Federation
Ekaterinburg , 62010, Russian Federation
Kazan , 42009, Russian Federation
Krasnoyarsk , 66003, Russian Federation
Kursk , 30500, Russian Federation
Moscow , 11704, Russian Federation
Moscow , 12701, Russian Federation
Moscow , 12912, Russian Federation
Nizhniy Novgorod , 60315, Russian Federation
Novosibirsk , 63000, Russian Federation
Odintsovo , 14300, Russian Federation
Perm , 61499, Russian Federation
Pyatigorsk , 35753, Russian Federation
Saint Petersburg , 19702, Russian Federation
Samara , 44309, Russian Federation
Smolensk , 21401, Russian Federation
St. Petersburg , 19435, Russian Federation
St. Petersburg , 19711, Russian Federation
St. Petersburg , 19737, Russian Federation
St.Petersburg , 19770, Russian Federation
Tomsk , 63405, Russian Federation
Tver , 17003, Russian Federation
Velikiy Novgorod , 21401, Russian Federation
Yaroslavl , 15000, Russian Federation
Belgrade , 11000, Serbia
Belgrade , 11000, Serbia
Kragujevac , 34000, Serbia
Nis , 18000, Serbia
Barcelona , 8003, Spain
Barcelona , 8035, Spain
Barcelona , 8036, Spain
Madrid , 28006, Spain
Malaga , 29010, Spain
Sevilla , 41009, Spain
Sevilla , 41950, Spain
Göteborg , 413 4, Sweden
Stockholm , 113 6, Sweden
Trabzon , 61080, Turkey
Chernihiv , 14001, Ukraine
Chernihiv , 14029, Ukraine
Ivano-Frankivsk , 76018, Ukraine
Ivano-Frankivsk , 76493, Ukraine
Kharkiv , 61103, Ukraine
Kharkiv , 61176, Ukraine
Kyiv , 3115, Ukraine
Lviv , 79000, Ukraine
Lviv , 79010, Ukraine
Odesa , 65009, Ukraine
Poltava , 36024, Ukraine
Ternopil , 46027, Ukraine
Vinnytsia , 21000, Ukraine
Zhytomyr , 10008, Ukraine
Preston , PR2 9, United Kingdom
Salford , M6 8H, United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.